Omacor Effects on Serum Lipids and Clinical Outcome

American Journal of Cardiology

Volumn 99, Issue 1, 2007, Pages 145-

  Ito, Matthew K ^a   Marrs, Joel ^a   Williams, Craig ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LIPID; OMEGA 3 FATTY ACID;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; HUMAN; HYPERTRIGLYCERIDEMIA; LETTER; LIPID BLOOD LEVEL; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDES;

EID: 33845707634     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.045     Document Type: Letter

References (3)

1. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 98 suppl (2006) 71I-76I
2. Dietary supplementation with n-3 polyunsaturated fatty acids and Vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 354 (1999) 447-455
3. Omacor® (omega-3-acid ethyl esters). Available at: http://www.omacorrx.com/About_OMACOR/About_OMACOR.html. Accessed September 25, 2006